American Renal Associates (NYSE:ARA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “American Renal Associates Holdings, Inc. is a provider of dialysis services primarily in the United States. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure. American Renal Associates Holdings, Inc. is based in Beverly, Massachusetts. “

ARA has been the topic of a number of other reports. Leerink Swann reaffirmed a “market perform” rating and issued a $22.00 target price (down from $27.00) on shares of American Renal Associates in a report on Wednesday, April 25th. Bank of America decreased their target price on American Renal Associates from $25.00 to $21.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, ValuEngine cut American Renal Associates from a “hold” rating to a “sell” rating in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $19.00.

Shares of American Renal Associates traded up $0.49, reaching $15.83, on Wednesday, Marketbeat.com reports. The stock had a trading volume of 306,504 shares, compared to its average volume of 163,807. The company has a market cap of $536.19 million, a P/E ratio of 25.95, a price-to-earnings-growth ratio of 0.81 and a beta of 2.00. American Renal Associates has a 1 year low of $9.91 and a 1 year high of $24.07. The company has a debt-to-equity ratio of 4.63, a current ratio of 1.15 and a quick ratio of 1.10.

American Renal Associates (NYSE:ARA) last released its quarterly earnings results on Tuesday, May 8th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.09 by $0.02. The firm had revenue of $194.67 million for the quarter, compared to the consensus estimate of $189.10 million. American Renal Associates had a return on equity of 16.88% and a net margin of 0.60%. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period last year, the business posted $0.07 EPS. analysts expect that American Renal Associates will post 0.7 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in ARA. The Manufacturers Life Insurance Company raised its holdings in American Renal Associates by 897.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 9,302 shares of the company’s stock worth $162,000 after purchasing an additional 8,369 shares during the period. Bank of New York Mellon Corp raised its holdings in American Renal Associates by 15.9% during the fourth quarter. Bank of New York Mellon Corp now owns 47,762 shares of the company’s stock valued at $831,000 after acquiring an additional 6,536 shares during the period. BlackRock Inc. raised its holdings in American Renal Associates by 6.2% during the fourth quarter. BlackRock Inc. now owns 630,825 shares of the company’s stock valued at $10,977,000 after acquiring an additional 37,034 shares during the period. Thrivent Financial For Lutherans bought a new stake in American Renal Associates during the fourth quarter valued at about $478,000. Finally, Deutsche Bank AG raised its holdings in American Renal Associates by 68.3% during the fourth quarter. Deutsche Bank AG now owns 40,873 shares of the company’s stock valued at $710,000 after acquiring an additional 16,582 shares during the period. 89.40% of the stock is currently owned by institutional investors.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.